The endogenous eNOS inhibitor asymmetric dimethyl arginine (ADMA) activates neutrophils and release of myeloperoxidase (MPO) leading to inhibition of dimethylaminohydrolases (DDAH), the enzyme catalyzing the breakdown of asymmetric dimethyl arginine (ADMA), and endothelial dysfunction [198]. Here, NOS3 is linked to endothelial dysfunction.